Sage shares data on retreatment with depression drug zuranolone

Sage Therapeutics has shared data from an open-label trial of zuranolone as it starts to remake the case for the drug following its phase 3 failure. The study found around half of major depressive disorder (MDD) patients who respond to zuranolone require retreatment and that outcomes for subsequent courses are comparable to the initial treatment.